I believe there are excellent opportunities in small-cap growth stocks today, particularly with multiple interest rate cuts on the horizon. One such opportunity is hVIVO (LSE: HVO), which provided a bullish H1 trading update yesterday (17 July)
In response, the stock rose 5% to 29p, but I reckon it’s set for further gains in the years ahead.
Record revenue growth
AIM-listed hVIVO is a specialist contract research organisation (CRO) and world leader in testing infectious disease products using human challenge clinical trials. These are where healthy volunteers are infected with pathogens to test diseases and potential treatments. This approach can save time and money for its customers (pharmaceutical firms) when conducting trials.
The company recruits volunteers through its own FluCamp platform then runs the trials at its designated quarantine facilities. It also offers standalone laboratory support and clinical consultancy services.
In the six months to the end of June, the firm’s revenue jumped 30.6% year on year to a record £35.6m. Its EBITDA profit margin improved from 19.1% in H1 2023 to approximately 24%. This was driven by enhanced operational efficiencies from running multiple quarantine facilities.
Meanwhile, its cash position increased to £37.1m from £31.3m the year before. The company has no debt.
For the full year, it reaffirmed revenue guidance of £62m (10.7% growth) and said EBITDA margins were anticipated to be at the upper end of market expectations.
We have full visibility over our expected 2024 revenues and continue to deliver on our sustainable growth strategy. The orderbook remains strong in spite of record revenue delivery in H1 2024. The recent Omicron characterisation study contract and the award of our largest field study to date are two key sales highlights for H1 2024. In addition, the current sales pipeline includes several advanced stage opportunities that we expect to convert in the coming months.
Yamin ‘Mo’ Khan, CEO of hVIVO, H1 2024 trading update
Risk and competition
One risk here is that human challenge studies are subject to stringent regulations. Any changes in such requirements or non-compliance could lead to delays, increased costs, or the halting of studies.
Plus, there are other firms around the world that compete with hVIVO in attracting contracts for clinical trials related to infectious diseases and respiratory illnesses. So it isn’t the only show in town.
New state-of-the-art facility
Despite these risks, things look very bright here. The company has just opened the world’s largest human challenge trial unit in London’s Canary Wharf. This will enable hVIVO to broaden its offerings to include new pathogen models and other services.
This new facility is expected to provide the capacity for £100m in revenue by 2028. With an assumed EBITDA margin of 24%, this gives a price-to-EBITDA ratio of around 8.5 for 2028. That’s attractive, assuming everything goes to plan, which isn’t guaranteed but looks increasingly likely.
For this year, the stock is trading on a forward price-to-earnings (P/E) multiple of 21. Again, I think that’s decent value for a fast-growing firm.
Finally, the stock is still 22% lower than a high of 38p reached back in 2021. I wouldn’t be surprised to see this one go on to hit new highs. If I didn’t already own the stock, I’d add it to my portfolio at 29p right now.
The post I’d snap up this growth stock at 29p without hesitation! appeared first on The Motley Fool UK.
5 Shares for the Future of Energy
Investors who don’t own energy shares need to see this now.
Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.
While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.
Open this new report — 5 Shares for the Future of Energy — and discover:
Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
How to potentially get paid by the weather
Electric Vehicles’ secret backdoor opportunity
One dead simple stock for the new nuclear boom
Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!
Grab your FREE Energy recommendation now
More reading
2 profitable ex-penny shares to consider for an ISA
Ben McPoland has positions in hVIVO Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
